Galderma Holding competitive analysis

Explore patent oppositions filed by Galderma Holding against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 16, 2026
Patent NumberTitleApplicantOpposition Date
Long Lasting Effect Of New Botulinum Toxin FormulationsMEDY TOXAug 24, 2021
Hyaluronic Acid-Based Gels Including Anesthetic AgentsALLERGAN INDUSTRIESep 30, 2020

Explore Galderma Holding's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 16, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jul 30, 2025Nemolizumab In The Treatment Of Atopic Dermatitis With Moderate To Severe Excoriation2

Latest PTAB cases involving Galderma Holding

Discover the latest PTAB cases involving Galderma Holding, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Galderma Holding with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 16, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GALDERMA HOLDING22 - -
ALLERGAN INDUSTRIE - 11 - 10
CABINET BECKER ET ASSOCIES5 - - -
J A KEMP45 - - -